Pfizer and BioNTech announced that their ongoing Phase 3 clinical vaccine trial confirms protection for at least six months after the second dose.
Pfizer and BioNTech announced that their ongoing Phase 3 clinical vaccine trial confirms protection for at least six months after the second dose.
Public health officials recommend if you are getting a two-dose vaccine, you should complete both doses for the strongest..
The European Commission president has announced that 70% of the adult population in the EU will receive at least one vaccine dose..